Xeris Biopharma Holdings (XERS) Liabilities and Shareholders Equity (2020 - 2026)

Xeris Biopharma Holdings' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $392.0 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 24.27% year-over-year to $392.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 14.64% YoY) and the FY2025 annual result came in at $383.5 million, up 18.72% from the prior year.
• Liabilities and Shareholders Equity was $392.0 million for Q1 2026 at Xeris Biopharma Holdings, up from $383.5 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $392.0 million in Q1 2026 and bottomed at $303.0 million in Q3 2022.
• A 5-year average of $336.0 million and a median of $328.8 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 130.85% — and 2023, when it decreased 6.36%.
• Xeris Biopharma Holdings' Liabilities and Shareholders Equity stood at $344.5 million in 2022, then dropped by 6.36% to $322.6 million in 2023, then increased by 0.14% to $323.1 million in 2024, then increased by 18.72% to $383.5 million in 2025, then rose by 2.21% to $392.0 million in 2026.
• Business Quant data shows XERS's Liabilities and Shareholders Equity at $392.0 million in Q1 2026, $383.5 million in Q4 2025, and $370.2 million in Q3 2025.